Overview

ILiAD Biotechnologies, LLC (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed 2 Phase 1 human clinical trials.


ILiAD Biotechnologies, LLC is a registered Delaware company founded in 2012.